Fidabio’s platform provides detailed information on affinity (Kd), kinetics (kon & koff) size, concentration, stoichiometry, conformational changes, oligomeric state, immunogenicity, and multiple binding events — directly in complex biological samples such as plasma, serum, cell lysate, or fermentation media.
Fida Biosystems has raised €5.0M across 1 funding round from 2 investors, most recently a round in Dec 2025. Based in Soborg, Denmark; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-12-17 | Other | €5.0M |
| EIFO,Fåhraeus Startup and Growth (FSG) |
| View deal → |
